Seminars in Oncology
Volume 33 , Pages 21-25 , February 2006

Immunomodulatory Effects of Rexinoids

  • Francine Foss

      Affiliations

    • Corresponding Author InformationAddress correspondence and reprint requests to Francine M. Foss, MD, Hematologic Malignancies, Medical Oncology, Yale Cancer Center, 333 Cedar St, New Haven, CT 06520

References 

  1. Farol LT , Hymes KB . Bexarotene (A clinical review) . Expert Rev Anticancer Ther . 2004;4:180–188
  2. Chambon P . The retinoid signaling pathway (Molecular and genetic analyses) . Semin Cell Biol . 1994;5:115–125
  3. Zhang C , Hazarika P , Ni X , et al.   Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells (Relevance to mechanism of therapeutic action) . Clin Cancer Res . 2002;8:1234–1240
  4. Sidell N , Chang B , Bhatti L . Upregulation by retinoic acid of interleukin-2 receptor mRNA in human T lymphocytes . Cell Immunol . 1993;146:28–37
  5. Gorgun G , Foss F . Immunomodulatory effects of RXR rexinoids (Modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox) . Blood . 2002;100:1399–1403
  6. Olsen E , Duvic M , Frankel A , et al.   Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma . J Clin Oncol . 2001;19:376–388
  7. Saleh MN , LeMaistre CF , Kuzel TM , et al.   Antitumor activity of BAD389IL-2 fusion toxin in mycosis fungoides . J Am Acad Dermatol . 1998;39:63–73
  8. LeMaistre CF , Saleh MN , Kuzel TM , et al.   Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2 . Blood . 1998;91:399–405
  9. Duvic M , Hymes K , Heald P , et al.   Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma (Multinational phase II-III trial results) . J Clin Oncol . 2001;19:2456–2471
  10. Duvic M , Martin AG , Kim Y , et al.   Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma . Arch Dermatol . 2001;137:581–593
  11. Foss F , Demierre MF , Divenuti G . A phase I trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma . Blood . 2005;106:454–457
  12. Edelson R , Berger C , Gasparro F , et al.   Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy (Preliminary results) . N Engl J Med . 1987;316:297–303
  13. Zic JA , Stricklin GP , Greer JP , et al.   Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy . J Am Acad Dermatol . 1996;35:935–945
  14. DeGrendele H . Current data with bexarotene (Targretin) in non–small cell lung cancer . Clin Lung Cancer . 2003;4:210–212
  15. Rigas JR , Dragnev KH . Emerging role of rexinoids in non–small cell lung cancer (Focus on bexarotene) . The Oncologist . 2005;10:22–33
  16. Yen T-C , Corpuz MR , Prudente RY , et al.   A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxol (Taxol) resistance in human non–small cell lung cancer . Clin Cancer Res . 2004;10:8656–8664

 This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.

 Prof Foss is a member of the speakers’ bureau for Ligand Pharmaceuticals.

PII: S0093-7754(05)00513-0

doi: 10.1053/j.seminoncol.2005.12.019

Seminars in Oncology
Volume 33 , Pages 21-25 , February 2006

Article Tools

* Image Usage & Resolution